Searching for serum tumor markers for colorectal cancer using a 2‐D DIGE approach

Identification of specific protein markers for colorectal cancer (CRC) could provide a basis for its early diagnosis and detection, as well as clues to the molecular mechanisms governing cancer progression. In the present study, 2‐D DIGE coupled with MS was used to screen for biomarker candidates in the serum proteome of ten human CRC samples and ten healthy control samples. After pooling identical amounts of serum proteins (based on total protein concentration), albumin/IgG was depleted under partially denaturing conditions. Subsequently, the serum samples were labeled with three different CyDyes, and separated by 2‐D DIGE. After analysis with the biological variation analysis module of the DeCyder software, only three spots were found to be significantly elevated in all patient groups (with ratios from 1.52 to 9.08), whereas five spots were significantly down‐regulated in patients (with ratios from −1.23 to −10.21) (t‐test; p<0.05). Finally, two potential biomarkers, Transaldolase 1 and thyroid receptor interactor, were chosen for validation and analysis by ELISA with the serum of 30 CRC patients and 30 healthy controls. The serum levels of the two proteins correlated well with the 2‐D DIGE results. Thus, 2‐D DIGE approaches show great promise for biomarker discovery in CRC.

[1]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[2]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[3]  A. Perl,et al.  Glutathione Levels and Sensitivity to Apoptosis Are Regulated by Changes in Transaldolase Expression* , 1996, The Journal of Biological Chemistry.

[4]  Wei Sun,et al.  Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis , 2007, Molecular & Cellular Proteomics.

[5]  F. Algaba,et al.  Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. , 2007, Journal of proteome research.

[6]  S. Woolf,et al.  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. , 2003, Gastroenterology.

[7]  C. Huck,et al.  Enrichment of low‐abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions , 2005, Electrophoresis.

[8]  M. Ünlü,et al.  Difference gel electrophoresis. A single gel method for detecting changes in protein extracts , 1997, Electrophoresis.

[9]  F. Casas,et al.  Thyroid hormone action in mitochondria. , 2001, Journal of molecular endocrinology.

[10]  R. Wait,et al.  Fluorescence two‐dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli , 2002, Proteomics.

[11]  S. Woolf.  The best screening test for colorectal cancer--a personal choice. , 2000, The New England journal of medicine.

[12]  Matthew Davison,et al.  Validation and development of fluorescence two‐dimensional differential gel electrophoresis proteomics technology , 2001, Proteomics.

[13]  D. Ahlquist.  Fecal occult blood testing for colorectal cancer. Can we afford to do this? , 1997, Gastroenterology clinics of North America.

[14]  Stephen O. David,et al.  A novel experimental design for comparative two‐dimensional gel analysis: Two‐dimensional difference gel electrophoresis incorporating a pooled internal standard , 2003, Proteomics.

[15]  A. Rustgi,et al.  Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. , 2005, Journal of proteome research.

[16]  W. Hogan,et al.  Major complications of coloscopy: Bleeding and perforation , 1975, The American Journal of Digestive Diseases.

[17]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[18]  J. Fandrey,et al.  Thyroid hormone induces hypoxia-inducible factor 1alpha gene expression through thyroid hormone receptor beta/retinoid x receptor alpha-dependent activation of hepatic leukemia factor. , 2008, Endocrinology.

[19]  A. Heck,et al.  Double Standards in Quantitative Proteomics , 2005, Molecular & Cellular Proteomics.

[20]  Yue Fan,et al.  2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. , 2009, Journal of proteome research.

[21]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[22]  R. Eddy,et al.  The human transaldolase gene (TALDO1) is located on chromosome 11 at p15.4-p15.5. , 1997, Genomics.

[23]  J. Terdiman,et al.  Colorectal cancer screening: scientific review. , 2003, JAMA.

[24]  Michelle A. Anderson,et al.  A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.

[25]  L. Moeller,et al.  Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1alpha and glycolytic genes. , 2005, Molecular endocrinology.

[26]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[27]  C. Sugawa,et al.  Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. , 1976, JAMA.

[28]  Yuquan Wei,et al.  Mechanism of Cancer Cell Adaptation to Metabolic Stress , 2009, Molecular & Cellular Proteomics.

[29]  E. Diamandis,et al.  Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Kay Dickersin,et al.  Shaping the future of biomarker research in breast cancer to ensure clinical relevance , 2007, Nature Reviews Cancer.

[31]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Lieberman,et al.  Accuracy of Screening for Fecal Occult Blood on a Single Stool Sample Obtained by Digital Rectal Examination: A Comparison with Recommended Sampling Practice , 2005, Annals of Internal Medicine.

[33]  C. Huck,et al.  Biomarker discovery in breast cancer serum using 2‐D differential gel electrophoresis/ MALDI‐TOF/TOF and data validation by routine clinical assays , 2006, Electrophoresis.

[34]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[35]  L. Arckens,et al.  Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. , 2004, Current opinion in biotechnology.